Topic: central nervous system
Steven Paul, M.D., left Eli Lilly after 17 years to “do something a bit more entrepreneurial." He went on to work on CNS disorders in small biotechs.
In roundworm models of Parkinson's, probiotic Bacillus subtilis lowered the buildup of alpha-synuclein in the brain—a culprit in the disease.
Looks like Biogen is going all in on Alzheimer’s disease—the Big Biotech is picking up a tau-targeting treatment from Ionis for $45 million upfront.
First, Sage Therapeutics was hit this month with a big failure in depression. Now, Minerva Neurosciences is following suit.
The duo kept details close to the vest but said Cerevance could net more than $170 million in milestones for each target Takeda moves forward.
Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.
After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.
The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.
Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.
Armed with $44 million, Arkuda Therapeutics is going after a protein that plays a role in neuronal health and lysosomal function to treat dementia.